Sotagliflozin is an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor. The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and ...
Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic ...